成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Home Cart 0 Sign in  

[ CAS No. 133407-82-6 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
Chemical Structure| 133407-82-6
Chemical Structure| 133407-82-6
Structure of 133407-82-6 * Storage: {[proInfo.prStorage]}

Please Login or Create an Account to: See VIP prices and availability

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

* Shipping: {[proInfo.prShipping]}

Quality Control of [ 133407-82-6 ]

Related Doc. of [ 133407-82-6 ]

Alternatived Products of [ 133407-82-6 ]
Product Citations

Product Citations

Zhiqiang Hu ; ?Yufen Zhang ; ?Yingchao Xie , et al. DOI:

Abstract: Toxoplasma gondii (T. gondii)-associated polymorphic effector proteins are crucial in parasite development and regulating host anti-T. gondii immune responses. However, the mechanism remains obscure. Here, it is shown that Toxoplasma effector dense granules 4 (GRA4) restricts host IFN-I activation. Infection with ?gra4 mutant T. gondii strain induces stronger IFN-I responses and poses a severe threat to host health. Mechanistically, GRA4 binds to phosphorylated TBK1 to promote TRIM27-catalyzed K48-ubiquitination at Lys251/Lys372 residues, which enhances its recognition by receptor p62, ultimately leading to TBK1 autophagic degradation. Furthermore, an avirulent ?gra4 strain (ME49?ompdc/gra4) is constructed for tumor immunotherapy due to its ability to enhance IFN-I production. Earlier vaccination with ME49?ompdc/gra4 confers complete host resistance to the tumor compared with the classical ME49?ompdc treatment. Notably, ME49?ompdc/gra4 vaccination induces a specific CD64 +MAR-1 +CD11b + dendritic cell subset, thereby enhancing T cell responses. Overall, these findings identify the negative role of T. gondii GRA4 in modulating host IFN-I signaling and suggest that GRA4 can be a potential target for the development of T. gondii vaccines and tumor immunotherapy.

Keywords: attenuated T. gondii ; selective autophagy ; toxoplasmosis ; tumor therapy ; type I interferon

Purchased from AmBeed:

Product Details of [ 133407-82-6 ]

CAS No. :133407-82-6 MDL No. :MFCD00674886
Formula : C26H41N3O5 Boiling Point : -
Linear Structure Formula :- InChI Key :TZYWCYJVHRLUCT-VABKMULXSA-N
M.W : 475.62 Pubchem ID :462382
Synonyms :
Z-Leu-Leu-Leu-al;Z-Leu-Leu-Leu-CHO;MGI-132;(S)-MG132;MG132 SSS
Chemical Name :Benzyl ((S)-4-methyl-1-(((S)-4-methyl-1-(((S)-4-methyl-1-oxopentan-2-yl)amino)-1-oxopentan-2-yl)amino)-1-oxopentan-2-yl)carbamate

Calculated chemistry of [ 133407-82-6 ]      Expand+

Physicochemical Properties

Num. heavy atoms : 34
Num. arom. heavy atoms : 6
Fraction Csp3 : 0.62
Num. rotatable bonds : 18
Num. H-bond acceptors : 5.0
Num. H-bond donors : 3.0
Molar Refractivity : 133.42
TPSA : 113.6 ?2

Pharmacokinetics

GI absorption : High
BBB permeant : No
P-gp substrate : Yes
CYP1A2 inhibitor : No
CYP2C19 inhibitor : Yes
CYP2C9 inhibitor : Yes
CYP2D6 inhibitor : No
CYP3A4 inhibitor : Yes
Log Kp (skin permeation) : -5.77 cm/s

Lipophilicity

Log Po/w (iLOGP) : 4.15
Log Po/w (XLOGP3) : 4.83
Log Po/w (WLOGP) : 3.44
Log Po/w (MLOGP) : 2.13
Log Po/w (SILICOS-IT) : 4.5
Consensus Log Po/w : 3.81

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 1.0
Egan : 0.0
Muegge : 1.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -4.77
Solubility : 0.008 mg/ml ; 0.0000168 mol/l
Class : Moderately soluble
Log S (Ali) : -6.95
Solubility : 0.0000535 mg/ml ; 0.000000112 mol/l
Class : Poorly soluble
Log S (SILICOS-IT) : -6.17
Solubility : 0.000322 mg/ml ; 0.000000676 mol/l
Class : Poorly soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 1.0 alert
Leadlikeness : 3.0
Synthetic accessibility : 4.66

Safety of [ 133407-82-6 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P305+P351+P338 UN#:N/A
Hazard Statements:H302-H315-H319-H335 Packing Group:N/A
GHS Pictogram:
Recommend Products
Same Skeleton Products
Historical Records
; ;